Arrowhead's Plozasiran Could Re-rate Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) reported a 171% year-over-year revenue surge to $75.3 million for its fiscal third quarter of 2026 on August 4. The company also announced the availability of its drug REDEMPLO for adults with Familial Chylomicronemia Syndrome (FCS) in Germany on August 17, following European Commission authorization in June 2026.

According to the source, the quarterly revenue beat Wall Street expectations of $52.7 million, driven by collaboration income and a doubling of REDEMPLO prescription volume in the U.S. However, the company's net loss attributable to shareholders widened to $194.2 million, or $1.36 per share, due to investments in research, development, and the commercial launch. Arrowhead ended the quarter with total cash resources of $1.56 billion.

Analyst Action

On August 6, H.C. Wainwright raised its price target on Arrowhead to $120 from $115 while reiterating a Buy rating. The firm cited a one-quarter pull-forward in the launch timeline for plozasiran, which targets severe hypertriglyceridemia (SHTG), and a new partnership with Madrigal. Analyst coverage reportedly views the company's $215 million purchase of a priority review voucher as a signal of management's conviction, backed by positive data from the SHASTA-3 and SHASTA-4 trials.

Bull Case

The bull case, as outlined in the source, is supported by pivotal Phase III efficacy data from two positive trials. This is said to provide meaningful clinical differentiation and reduce regulatory risk. Durable reductions in triglycerides and acute pancreatitis events are cited as strengthening the therapy's long-term value. A cash balance of $1.57 billion provides a substantial liquidity runway to complete late-stage programs and fund expansion. Partnership income from companies like Novartis, Sarepta, and Madrigal is also noted as validating the underlying platform and providing non-dilutive financing.

Bear Case

The bear case centers on persistent unprofitability. The source states that quarterly operating losses were $170.1 million in Q3, which limits return generation and could increase reliance on external capital. Volatile cash flow and uneven cash conversion create funding uncertainty, leaving the company dependent on milestone receipts. The commercial ramp for REDEMPLO remains unproven, with the drug generating just $2.4 million in early sales. Long-term adoption will reportedly depend on physician education, reimbursement outcomes, and competition.

The core question, according to the source, is whether commercial scaling and pipeline momentum can outpace the heavy cash burn to drive a long-term stock re-rating.